

# Effects of 17-hydroxywortmannin on serine/threonine-protein kinases in human blood platelets

Markus Kocher and Kenneth J. Clemetson

*Theodor Kocher Institute, University of Berne, Freiestrasse 1, CH-3012 Berne, Switzerland*

Received 9 August 1991

Protein kinases are involved in signal transduction in human blood platelets. A number of renaturable protein kinases have increased in vitro activities compared to controls due to covalent modifications when intact platelets are activated by thrombin. The effect of the platelet inhibitor 17-hydroxywortmannin (HWT) on these protein kinases was investigated in intact platelets and in vitro. HWT inhibits the increase in activity of these protein kinases but it does not interact directly with their catalytic subunits. We conclude that HWT blocks a step in signal transduction which is necessary to activate these protein kinases via covalent modifications.

Platelet, Protein kinase, Aggregation, Signal transduction, Thrombin, Fungal metabolite

## 1. INTRODUCTION

Stimulation of platelets with thrombin induces the GTP-dependent activation of phospholipase C [1] which cleaves membrane-bound phosphatidylinositol bisphosphate (PIP<sub>2</sub>) to produce the second messengers inositol 1,4,5-trisphosphate (IP<sub>3</sub>) and diacylglycerol (DAG). IP<sub>3</sub> triggers the release of calcium from the storage granules into the cytosol [2] while DAG activates protein kinase C [3] that phosphorylates a number of substrates [4–8]. Other pathways of platelet activation are less well characterized and may also include phosphorylation cascades.

The activity of a group of protein kinases could be restored by renaturation after electrophoresis and transfer to PVDF membranes [9]. Kinase activity was monitored with [ $\gamma$ -<sup>32</sup>P]ATP. Bands on the blots were detected by autoradiography. Phosphoserine and phosphothreonine were predominantly labelled and analysis of the phosphorylated protein species revealed that with most of the protein kinases, bovine serum albumin and the kinases themselves (variable amount of autophosphorylation) contained most of the <sup>32</sup>P-label [10]. Some of these protein kinases show higher in vitro activities on the blots when intact platelets were activated and therefore may somehow be involved in signal transduction pathways. The changes in activity are most proba-

bly due to covalent modifications as they are conserved during the denaturation- and renaturation-treatment.

17-Hydroxywortmannin (HWT) is a derivative of the sterol-like fungal metabolite wortmannin [11]. It inhibited respiratory burst and secretion in neutrophils without directly affecting PKC [12]. Since HWT shows relatively specific effects on platelet activation (von Tschanner, V. and Clemetson, K. J., submitted), renaturation of blotted proteins was used to investigate its effects on the activation in intact platelets and in vitro activities of the renaturable and covalently modified protein kinases from human blood platelets in order to correlate these with other platelet reactions.

## 2. MATERIALS AND METHODS

### 2.1. Materials

Apyrase, bovine serum albumin (fraction V and fatty acid free, fraction V), phorbol myristyl acetate (PMA), ionomycin and the pre-stained molecular mass markers were from Sigma, St. Louis, MO. Thrombin was from Merck, Zurich. Ilprost was kindly donated by Schering AG, Zurich. HEPES was from Calbiochem, Lucerne. Guanidine-HCl was from Fluka, Buchs. and Nonidet P-40 was from Grogg, Berne. [ $\gamma$ -<sup>32</sup>P]ATP (3000 Ci/mmol) was from Amersham International, England. The PVDF membranes (Immobilon-P) were from Millipore, Bedford, MA. HWT, {1,7,8,9,9a,11b-octahydro-11-acetoxy-9-hydroxy-1-(methoxymethyl)-9a,11b-dimethyl-3H,6bH-furo[4,3,2-de]indeno[4,5-h][2]benzopyran-3,6-dione} and the inactive wortmannin derivative IWT {6b,7,9a,10,11,11b-hexahydro-5-hydroxy-4-hydroxymethylen-1-methoxymethyl-9a,11b-dimethyl-1H,6H-indeno[4,5-h][2]benzopyran-3,6,9(4H,8H)-trione} were supplied by Dr T.G. Payne, Preclinical Research, Sandoz Ltd, Basle, Switzerland.

### 2.2. Isolation of human platelets

Buffy coats were obtained from the Swiss Red Cross in Berne (FDA four bag system) approximately 15 h after collection. Buffy coat dilution buffer (0.1 volume) was added to give an end concentration of 10 mM sodium citrate and 0.15 U/ml apyrase and the suspension was

**Abbreviations:** HWT, 17-hydroxywortmannin, PVDF, polyvinylidene difluoride, fMLP, *N*-formyl-methionylleucylphenylalanine, PMA, phorbol myristyl acetate, IWT, inactive wortmannin derivative.

**Correspondence address:** K.J. Clemetson, Theodor Kocher Institute, University of Berne, Freiestrasse 1, CH-3012 Berne, Switzerland. Fax (41) (31) 65 37 99.

centrifuged at  $150\times g$  for 15 min. The platelet-rich plasma was acidified to pH 6.5 with 150 mM citric acid, iloprost was added to an end concentration of 1 ng/ml, and centrifugation at  $500\times g$  for 15 min pelleted the platelets. The platelets were washed twice with 100 vols of 137 mM NaCl, 11 mM glucose, 11 mM sodium citrate, 0.2 U/ml apyrase, 0.25% BSA, pH 6.5, and then resuspended in 137 mM NaCl, 2 mM KCl, 1 mM  $MgCl_2$ , 1 mM  $CaCl_2$ , 0.4 mM  $NaH_2PO_4$ , 5.6 mM glucose, 5 mM HEPES, 1 U/ml apyrase pH 7.5 to an end concentration of  $10^9$  platelets per ml. Experiments were performed at  $37^\circ C$ . HWT was added from stock solutions in  $Me_2SO$  to yield a final  $Me_2SO$  concentration of 0.1%, which did not change the pattern of phosphorylation in the renatured kinases.

### 2.3 Kinase assays

Samples were solubilized immediately in SDS-PAGE sample buffer at a concentration of 2.3% SDS, 0.1% dithiothreitol, 0.1 mM EDTA, 62.5 mM Tris, 10% glycerol, pH 6.8, vortexed and boiled for 2 min. Separation of platelet proteins in 7.5% polyacrylamide gels [13] and the transfer to PVDF membranes were as described [14]. Renaturation and kinase reactions were performed according to Ferrell and Martin [10]. The X-ray films were analysed on a DD2 densitometer from Kipp & Zonen connected to a chart recorder.

### 2.4 In vitro treatment

After renaturation and blocking, sections of the blots were treated with HWT in 30 mM Tris, 10 mM  $MgCl_2$ , 2 mM  $MnCl_2$ , pH 7.5 for 10 min at room temperature. They were washed once with the same buffer without HWT and then incubated with the kinase reaction buffer [10].

## 3. RESULTS

Washed human platelets were preincubated with different concentrations of HWT for 10 min and then stimulated with thrombin (Fig. 1). Blots from untreated control or thrombin-stimulated platelets showed patterns of labelled bands similar to those reported earlier [10]. A combination of the phorbol ester PMA and ionomycin induced the activities of the protein kinases similar to that induced by thrombin (not shown). Preincubation of unstimulated control platelets with HWT had no effect on the activities of the renatured protein kinases (Fig. 1A). HWT preincubation inhibited the increase of activity of PK 48, PK 52, PK




Fig. 1 Effect of HWT treatment and thrombin stimulation in intact platelets on the *in vitro* activities of the renaturable protein kinases from human platelets. Autoradiogram of PVDF-membranes with renatured proteins labelled *in vitro* with  $[\gamma\text{-}^{32}P]\text{ATP}$  from a typical experiment where platelets were preincubated for 10 min with different concentrations of HWT (A) Shows unstimulated platelets preincubated with and without HWT (B) Shows platelets activated with 1 U/ml thrombin. The 0 time samples were taken just before the addition of thrombin, then the other samples were taken after times as indicated and all were treated as described in Materials and Methods. The stimulations were performed with washed platelets from the same buffy coat. All the blots were treated the same way and autoradiographed together on the same film. Molecular mass markers are indicated in kilodaltons.




Fig 2 Kinetics of PK 60 activation. Densitometric analysis of the autoradiograms of several similar experiments of the activity of PK 60. The amount of processed  $^{32}\text{P}$  was measured as peak surfaces relative to the control values at 0 time that were set to 100. The symbols are  $\circ$  control,  $n=4$ ,  $\nabla$  HWT  $10^{-5}$  M alone,  $n=2$ ,  $\blacktriangle$  HWT  $10^{-5}$  M,  $n=3$ ,  $\bullet$  HWT  $10^{-7}$  M,  $n=2$ , both stimulated with thrombin 1 U/ml  $\bullet$  thrombin 1 U/ml,  $n=4$ .

56, PK 60, PK 64 and PK 170 after thrombin treatment (Fig 1B). The inactive wortmannin derivative (IWT) had no effect on the activities of the renatured protein kinases from either unstimulated control platelets or from thrombin-stimulated platelets (not shown). The activities of PK 82, PK 86 and PK 94 were little affected when platelets were activated with thrombin. HWT did not change this. The activity of PK 150 after thrombin stimulation was increased although the difference was very small. This was not inhibited by HWT. PK 150 activity was also increased by PMA alone and not affected by HWT (not shown).

PK 60 was the strongest labelled band detected in this kinase assay method in platelets and densitometric analysis of the relative intensities of these bands (Fig 2) revealed that the  $\text{IC}_{50}$  of HWT was approximately  $10^{-7}$  M. At  $10^{-5}$  M HWT the increase in activity was completely inhibited. At HWT concentrations of  $10^{-8}$  M and lower, the time course of the kinase activity followed roughly the time course of thrombin activation (data not shown,  $n=1$ ).

To investigate whether HWT directly affected the protein kinases, the renatured proteins on the membranes were subjected to *in vitro* HWT treatment with different concentrations after renaturation and blocking and before incubation with the radioactive ATP (Fig 3). HWT had no effect on any renaturable protein kinase *in vitro*. The differences in the activities of the renatured protein kinases from control and from thrombin treated platelets were still conserved.

#### 4 DISCUSSION

From two previous series of experiments the renaturable protein kinases from platelets could already be



Fig 3 Comparison of HWT-treatment in intact platelets and *in vitro*. Platelets were preincubated with HWT at different concentrations as indicated above for 10 min. They were then treated with (T) or without (C) thrombin at a concentration of 1 U/ml for 20 s. After renaturation and blocking the four sections of the blot were treated with different concentrations of HWT *in vitro* for 10 min as indicated on the 'in vitro' side of the top line. The left part of the blot was treated with buffer alone. All four pieces were then treated with  $50 \mu\text{Ci/ml}$   $[\gamma\text{-}^{32}\text{P}]\text{ATP}$  for 30 min. Autoradiograms were prepared from the washed and dried blots. Molecular mass markers are indicated in kilodaltons.

divided into different groups [10] according to the changes in their renatured *in vitro* activity with different platelet activators in intact platelets. PK 52, PK 56, PK 60, PK 64 and PK 170 were activated when platelets were treated with a combination of phorbol ester and ionophore indicating their possible involvement in signal transduction downstream of  $\text{PIP}_2$ -breakdown. PK 52 and PK 64 are most probably activated by phosphorylation as their activation is inhibited by the protein kinase inhibitor staurosporine and PK 52, PK 60, PK 150 and PK 170 are activated by dephosphorylation or another mechanism since their activation was enhanced by staurosporine [14].

In neutrophils HWT inhibited the fMLP-induced respiratory burst at a concentration of  $10^{-6}$  M but the PMA-induced burst was not affected suggesting that HWT does not inhibit PKC directly and it does not interfere with the phospholipase C mediated rise in intracellular calcium concentration (via  $\text{IP}_3$ ) and therefore a novel signal transduction pathway was proposed [12]. There is evidence that DAG production and the resulting PKC activation is not only phospholipase C dependent and the activation of phospholipase D to produce DAG via another pathway to fully activate PKC was proposed [15]. This leads to the speculation that PKC activation is blocked indirectly by HWT by reducing DAG production via the other pathway. Since in platelets HWT inhibits aggregation and pleckstrin phosphorylation (von Tscharnai, V and Clemetson, K J, submitted) and the increase in activity of several Ser/Thr protein kinases (this paper) at a comparable concentration ( $10^{-4}$  M) to that effective in neutrophils, a similar signal transduction pathway might be affected that leads to the activation of protein kinases. DAG is

not enough to activate the renaturable protein kinases since PMA alone only stimulates one of them (PK 150) and they are therefore not activated via PKC alone. The way in which PKC itself is activated suggests that it is not detected in this assay system, as it requires at least phosphatidylserine and DAG for activation [16]. As all the protein kinases inhibited by HWT (PK 48, PK 52, PK 56, PK 60, PK 64 and PK 170) are affected to roughly the same extent (Fig. 1) they may all be involved in a later phase of platelet activation. HWT blocks a step in signal transduction which is necessary to activate these protein kinases via covalent modifications. It was suggested that this may be a G-protein dependent step leading to phospholipase D activation [17].

While staurosporine directly blocks the protein kinases in a general way but cannot prevent their activation and even induces the activation of PK 52, PK 60 and PK 170 directly [14], HWT probably inhibits the initiation of the pathway leading to their activation. The above results indicate that HWT is a useful tool for differentiating between early and late signal transduction events. Protein kinases may be involved in the regulation of other enzymes or receptors by phosphorylation and together with phosphatases may be responsible for amplification or fine tuning of signals. Since aggregation of platelets is not completely inhibited by staurosporine [18] the activation of PK 52, PK 56, PK 60, PK 64 and PK 170 is not sufficient to lead to platelet aggregation. Their inhibition by HWT correlates well with the inhibition of the late phase of platelet activation including aggregation. Other similarities are found when the kinetics of activation of these kinases are compared to the increases in Tyr-phosphorylation of platelets. Tyr-phosphorylation increases also in a group of proteins in platelets 3 minutes after thrombin stimulation [19]. Although it remains unresolved whether the renaturable protein kinases are involved in the signal transduction leading to aggrega-

tion and secretion the results obtained here suggest that activation of these protein kinases goes in parallel with these processes.

*Acknowledgements* We thank Prof. E. F. Lüscher for carefully reading and criticizing the manuscript. We also thank the Swiss Red Cross Central Laboratory for providing buffy coats. This work was supported by the Swiss National Foundation Grant 31 25633 88.

## REFERENCES

- [1] Wilson, B. B., Neufeld, E. J. and Majerus, P. W. (1985) *J. Biol. Chem.* 260, 1046–1051.
- [2] Berridge, M. J. and Irvine, R. F. (1989) *Nature* 341, 197–205.
- [3] Nishizuka, Y. (1984) *Nature* 308, 693–698.
- [4] Kaibuchi, K., Takai, Y., Sawamura, M., Hoshijima, M., Fujikura, T. and Nishizuka, Y. (1983) *J. Biol. Chem.* 258, 6701–6704.
- [5] Naka, M., Nishikawa, M., Adelstein, R. S. and Hikada, H. (1983) *Nature* 306, 490–492.
- [6] Werth, D. K., Nudel, J. E. and Pastan, I. (1983) *J. Biol. Chem.* 258, 11426–11432.
- [7] Connolly, T. M., Lawing, W. J. Jr. and Majerus, P. W. (1986) *Cell* 46, 951–958.
- [8] Gould, K. L., Woodgett, J. R., Cooper, J. A., Buff, J. E., Shalloway, D. and Hunter, T. (1985) *Cell* 42, 849–856.
- [9] Celenza, J. L. and Carlson, M. (1986) *Science* 233, 1175–1180.
- [10] Ferrell, J. E. and Martin, G. S. (1989) *J. Biol. Chem.* 264, 20723–20729.
- [11] Baggiolini, M., Dewald, B., Schnyder, J., Ruch, W., Cooper, P. H. and Payne, T. G. (1987) *Exp. Cell Res.* 169, 408–418.
- [12] Dewald, B., Thelen, M. and Baggiolini, M. (1988) *J. Biol. Chem.* 263, 16179–16184.
- [13] Laemmli, U. K. (1970) *Nature* 227, 680–685.
- [14] Kocher, M. and Clemetson, K. J. (1991) *Biochem. J.* 275, 301–306.
- [15] Reinhold, S. L., Prescott, S. M., Zimmerman, G. A. and McIntyre, T. N. (1990) *FASEB J.* 4, 208–214.
- [16] Nishizuka, Y. (1986) *Science* 233, 305–311.
- [17] Bonser, R. W., Thompson, R. W., Randall, R. W., Tateson, J. E., Spacey, G. D., Hodson, H. F. and Garland, L. G. (1991) *Br. J. Pharmacol.* 103, 1237–1241.
- [18] Watson, S. P. and Hambleton, S. (1989) *Biochem. J.* 258, 479–485.
- [19] Ferrell, J. E. and Martin, G. S. (1989) *Proc. Natl. Acad. Sci. USA* 86, 2234–2238.